RNAi Pioneer Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TransCode Therapeutics has added renowned RNA biology expert Dr. Phillip D. Zamore to its Scientific Advisory Board, potentially strengthening the company's RNA-targeted cancer therapy research and development strategy.
TransCode Therapeutics has appointed Dr. Phillip D. Zamore, a leading researcher in RNA interference (RNAi), to its Scientific Advisory Board. Dr. Zamore, who is currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, brings significant expertise in RNA biology and gene silencing mechanisms to the clinical-stage oncology company.
As a co-founder of Alnylam Pharmaceuticals and a member of the National Academy of Sciences, Zamore's appointment signals potential strategic advancement for TransCode's cancer therapy programs. The company focuses on developing RNA therapeutics using its proprietary TTX nanoparticle platform, with a primary focus on treating metastatic tumors.
Zamore's election to the Scientific Advisory Board could provide critical insights into improving RNA delivery techniques and expanding therapeutic approaches for targeting genetic markers associated with cancer metastasis. His foundational work in RNA biology may help TransCode refine its lead therapeutic candidate, TTX-MC138, which targets tumors overexpressing microRNA-10b.
The addition of such a distinguished researcher underscores TransCode's commitment to innovative cancer treatment strategies and potentially positions the company to make significant advances in RNA-based therapeutic technologies.